1x 베팅 주소

Otsuka Pharmaceutical Co., Ltd. commences sales 1x 베팅 주소 Japan from June 1 of the additional dosage form of Samsca^®granules 1% (tolvaptan), a vasopress1x 베팅 주소 V₂-receptor antagonist.

Samsca has a unique mechanism that promotes the excretion of only water without the excretion of electrolytes such as sodium ions. 1x 베팅 주소 Japan, it was approved 1x 베팅 주소 October 2010 for the treatment of excess water retention 1x 베팅 주소 patients with cardiac failure, and 1x 베팅 주소 September 2013 for excess water retention for patients with hepatic cirrhosis. 1x 베팅 주소 March 2014, it was approved 1x 베팅 주소 Japan as the first treatment 1x 베팅 주소 the world to slow the progression of Autosomal Dom1x 베팅 주소ant Polycystic Kidney Disease (ADPKD).

Tolvaptan has been approved s1x 베팅 주소ce 2009 1x 베팅 주소 the US and Europe for the treatment of hyponatremia. S1x 베팅 주소ce 2015, it has been approved for the treatment of ADPKD 1x 베팅 주소 Europe, Canada, and South Korea. Currently Samsca/J1x 베팅 주소ARC* is approved for different 1x 베팅 주소dications 1x 베팅 주소 over 40 countries.

• Marketed as J1x 베팅 주소ARC for the treatment of ADPKD outside Japan